Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

37.76 +0.20 (+0.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 337,146
Open 37.66
Bid (Size) 37.60 (1)
Ask (Size) 38.81 (1)
Prev. Close 37.56
Today's Range 37.58 - 37.89
52wk Range 26.19 - 47.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Foreboding Sign Looms Over Genmab's Chart
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Genmab
 
Via Benzinga

Performance

YTD
-12.25%
-12.25%
1 Month
+3.78%
+3.78%
3 Month
-12.25%
-12.25%
6 Month
+11.72%
+11.72%
1 Year
+3.06%
+3.06%

More News

Read More
Earnings Outlook For Genmab
Via Benzinga
Alkermes Stock Sees Rising Relative Price Strength
Via Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark
Via Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Via Investor's Business Daily
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
Via Investor's Business Daily
3 Biotech Companies to Watch in 2023
Via InvestorPlace
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
Via Investor's Business Daily
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
From Genmab A/S
Via Business Wire
Our 7 Top Biotech Stock Picks for 2023
Via InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
Via Investor's Business Daily
3 Hot Stocks That Could Live Up to Their Lofty Valuations
Via The Motley Fool
Is AbbVie Stock a Buy Now?
Via The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.